Arthur L. Burnett II, MD, MBA, FACS, presented “Ethnic Disparities in Sexual Dysfunction Outcomes After Prostate Cancer Treatment: Myth or Reality?” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Burnett II, Arthur L. “Ethnic Disparities in Sexual Dysfunction Outcomes After Prostate Cancer Treatment: Myth or Reality?” January 23rd, 2020. Accessed Nov 2024. https://dev.grandroundsinurology.com/ethnic-disparities-in-sexual-dysfunction-outcomes-after-prostate-cancer-treatment-myth-or-reality/
Ethnic Disparities in Sexual Dysfunction Outcomes After Prostate Cancer Treatment: Myth or Reality? – Summary:
Arthur L. Burnett II, MD, MBA, FACS, Professor of Urology and Director of the Basic Science Laboratory in Neuro-Urology at Johns Hopkins University School of Medicine, discusses potential disparities that exist among different ethnic minorities that may impact treatment-related sexual dysfunction following treatment for prostate cancer. He goes on to discuss racial and ethnic disparities in the prostate cancer treatment landscape, review of prior studies that discuss the possible psychosocial and cultural determinants that impact these outcomes, as well as propose possible approaches to address the problem of sexual dysfunction after prostate cancer treatment amongst various ethnic minority groups.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Burnett delivered this educational activity during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Arthur L. Burnett II, MD, MBA, FACS, is a Professor in the Department of Urology and Director of the Basic Science Laboratory in Neuro-Urology at Johns Hopkins University School of Medicine. His professional appointments at the Johns Hopkins Hospital include Director of the Male Consultation Clinic and Clinician-Scientist at the James Buchanan Brady Urological Institute. Dr. Burnett earned his undergraduate degree in biology from Princeton University and his medical degree at Johns Hopkins University School of Medicine. He completed his internship and residency in surgery and, subsequently, residency and fellowship in urology at the Johns Hopkins Hospital. After completing his urology residency, Dr. Burnett received an American Foundation of Urologic Disease New Investigator Award to continue research into the regulatory mechanisms of penile erection. Since then, he has maintained an active laboratory in neuro-urology.
Dr. Burnett is recognized as a world-authority in the science and medicine of male erectile dysfunction. He has contributed original discoveries about the nitric oxide biochemical mechanisms in erectile tissue that have paved the way for the clinical development of oral medications to treat erectile dysfunction. He has also done pioneering work developing therapies to protect the penile nerve function required for improved erectile function recovery after radical prostatectomy.
Dr. Burnett has written more than 150 original peer-reviewed articles, along with numerous additional articles, editorials, and book chapters, relating to his biomedical research and clinical activities. His work has appeared in many major journals including Science, Nature Medicine, Proceedings of the National Academy of Sciences, Journal of Urology, Urology, and Journal of Andrology. He is a Fellow of the American College of Surgeons, as well as a member of the American Urological Association, the Sexual Medicine Society of North America, the International Society for Sexual Medicine, the Society of Genitourinary Reconstructive Surgeons, the Society for Urodynamics and Female Urology, and the Society of Black Academic Surgeons. He has sat on various advisory committees, including the Urology Study Section, the National Institutes of Health Center for Scientific Review, and the FDA Advisory Committee for Reproductive Health Drugs.
